259 related articles for article (PubMed ID: 33053221)
1. A Versatile Nonviral Delivery System for Multiplex Gene-Editing in the Liver.
Gong J; Wang HX; Lao YH; Hu H; Vatan N; Guo J; Ho TC; Huang D; Li M; Shao D; Leong KW
Adv Mater; 2020 Nov; 32(46):e2003537. PubMed ID: 33053221
[TBL] [Abstract][Full Text] [Related]
2. Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of
Qiu M; Glass Z; Chen J; Haas M; Jin X; Zhao X; Rui X; Ye Z; Li Y; Zhang F; Xu Q
Proc Natl Acad Sci U S A; 2021 Mar; 118(10):. PubMed ID: 33649229
[TBL] [Abstract][Full Text] [Related]
3. Fast and Efficient CRISPR/Cas9 Genome Editing In Vivo Enabled by Bioreducible Lipid and Messenger RNA Nanoparticles.
Liu J; Chang J; Jiang Y; Meng X; Sun T; Mao L; Xu Q; Wang M
Adv Mater; 2019 Aug; 31(33):e1902575. PubMed ID: 31215123
[TBL] [Abstract][Full Text] [Related]
4. Co-delivery of Sorafenib and CRISPR/Cas9 Based on Targeted Core-Shell Hollow Mesoporous Organosilica Nanoparticles for Synergistic HCC Therapy.
Zhang BC; Luo BY; Zou JJ; Wu PY; Jiang JL; Le JQ; Zhao RR; Chen L; Shao JW
ACS Appl Mater Interfaces; 2020 Dec; 12(51):57362-57372. PubMed ID: 33301289
[TBL] [Abstract][Full Text] [Related]
5. Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing.
Yin H; Song CQ; Suresh S; Wu Q; Walsh S; Rhym LH; Mintzer E; Bolukbasi MF; Zhu LJ; Kauffman K; Mou H; Oberholzer A; Ding J; Kwan SY; Bogorad RL; Zatsepin T; Koteliansky V; Wolfe SA; Xue W; Langer R; Anderson DG
Nat Biotechnol; 2017 Dec; 35(12):1179-1187. PubMed ID: 29131148
[TBL] [Abstract][Full Text] [Related]
6. Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol.
Xu YX; Redon V; Yu H; Querbes W; Pirruccello J; Liebow A; Deik A; Trindade K; Wang X; Musunuru K; Clish CB; Cowan C; Fizgerald K; Rader D; Kathiresan S
Atherosclerosis; 2018 Jan; 268():196-206. PubMed ID: 29183623
[TBL] [Abstract][Full Text] [Related]
7. CES1-Triggered Liver-Specific Cargo Release of CRISPR/Cas9 Elements by Cationic Triadic Copolymeric Nanoparticles Targeting Gene Editing of PCSK9 for Hyperlipidemia Amelioration.
Zhao Y; Li Y; Wang F; Gan X; Zheng T; Chen M; Wei L; Chen J; Yu C
Adv Sci (Weinh); 2023 Jul; 10(19):e2300502. PubMed ID: 37083231
[TBL] [Abstract][Full Text] [Related]
8. A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing.
Finn JD; Smith AR; Patel MC; Shaw L; Youniss MR; van Heteren J; Dirstine T; Ciullo C; Lescarbeau R; Seitzer J; Shah RR; Shah A; Ling D; Growe J; Pink M; Rohde E; Wood KM; Salomon WE; Harrington WF; Dombrowski C; Strapps WR; Chang Y; Morrissey DV
Cell Rep; 2018 Feb; 22(9):2227-2235. PubMed ID: 29490262
[TBL] [Abstract][Full Text] [Related]
9. Finely tuned ionizable lipid nanoparticles for CRISPR/Cas9 ribonucleoprotein delivery and gene editing.
Im SH; Jang M; Park JH; Chung HJ
J Nanobiotechnology; 2024 Apr; 22(1):175. PubMed ID: 38609947
[TBL] [Abstract][Full Text] [Related]
10. Integrating Combinatorial Lipid Nanoparticle and Chemically Modified Protein for Intracellular Delivery and Genome Editing.
Chang J; Chen X; Glass Z; Gao F; Mao L; Wang M; Xu Q
Acc Chem Res; 2019 Mar; 52(3):665-675. PubMed ID: 30586281
[TBL] [Abstract][Full Text] [Related]
11. Reduced Blood Lipid Levels With In Vivo CRISPR-Cas9 Base Editing of ANGPTL3.
Chadwick AC; Evitt NH; Lv W; Musunuru K
Circulation; 2018 Feb; 137(9):975-977. PubMed ID: 29483174
[No Abstract] [Full Text] [Related]
12. Scaffold-mediated non-viral delivery platform for CRISPR/Cas9-based genome editing.
Chin JS; Chooi WH; Wang H; Ong W; Leong KW; Chew SY
Acta Biomater; 2019 May; 90():60-70. PubMed ID: 30978509
[TBL] [Abstract][Full Text] [Related]
13. Lipid-Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Components.
Kazemian P; Yu SY; Thomson SB; Birkenshaw A; Leavitt BR; Ross CJD
Mol Pharm; 2022 Jun; 19(6):1669-1686. PubMed ID: 35594500
[TBL] [Abstract][Full Text] [Related]
14. Gene editing for dyslipidemias: New tools to "cut" lipids.
Stankov S; Cuchel M
Atherosclerosis; 2023 Mar; 368():14-24. PubMed ID: 36725417
[TBL] [Abstract][Full Text] [Related]
15. Nonviral gene editing via CRISPR/Cas9 delivery by membrane-disruptive and endosomolytic helical polypeptide.
Wang HX; Song Z; Lao YH; Xu X; Gong J; Cheng D; Chakraborty S; Park JS; Li M; Huang D; Yin L; Cheng J; Leong KW
Proc Natl Acad Sci U S A; 2018 May; 115(19):4903-4908. PubMed ID: 29686087
[TBL] [Abstract][Full Text] [Related]
16. Direct Cytosolic Delivery of CRISPR/Cas9-Ribonucleoprotein for Efficient Gene Editing.
Mout R; Ray M; Yesilbag Tonga G; Lee YW; Tay T; Sasaki K; Rotello VM
ACS Nano; 2017 Mar; 11(3):2452-2458. PubMed ID: 28129503
[TBL] [Abstract][Full Text] [Related]
17. Genome Editing in a Wide Area of the Brain Using Dendrimer-Based Ternary Polyplexes of Cas9 Ribonucleoprotein.
Taharabaru T; Yokoyama R; Higashi T; Mohammed AFA; Inoue M; Maeda Y; Niidome T; Onodera R; Motoyama K
ACS Appl Mater Interfaces; 2020 May; 12(19):21386-21397. PubMed ID: 32315156
[TBL] [Abstract][Full Text] [Related]
18. Strategies for nonviral nanoparticle-based delivery of CRISPR/Cas9 therapeutics.
Chen F; Alphonse M; Liu Q
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 May; 12(3):e1609. PubMed ID: 31797562
[TBL] [Abstract][Full Text] [Related]
19. CRISPR-Cas12a delivery by DNA-mediated bioresponsive editing for cholesterol regulation.
Sun W; Wang J; Hu Q; Zhou X; Khademhosseini A; Gu Z
Sci Adv; 2020 May; 6(21):eaba2983. PubMed ID: 32490205
[TBL] [Abstract][Full Text] [Related]
20. LNP-mediated delivery of CRISPR RNP for wide-spread in vivo genome editing in mouse cornea.
Mirjalili Mohanna SZ; Djaksigulova D; Hill AM; Wagner PK; Simpson EM; Leavitt BR
J Control Release; 2022 Oct; 350():401-413. PubMed ID: 36029893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]